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Abstract The TNF-related apoptosis inducing ligand
TRAIL is a member of the TNF superfamily that has been
firstly studied and evaluated for its anti-cancer activity, and
the insights into its biology have already led to the iden-
tification of several TRAIL-based anticancer strategies
with strong clinical therapeutic potentials. Nonetheless, the
TRAIL system is far more complex and it can lead to a
wider range of biological effects other than the ability of
inducing apoptosis in cancer cells. By virtue of the dif-
ferent receptors and the different signalling pathways
involved, TRAIL plays indeed a role in the regulation of
different processes of the innate and adaptive immune
system and this feature makes it an intriguing molecule
under consideration in the development/progression/treat-
ment of several immunological disorders. In this context,
central nervous system represents a peculiar anatomic site
where, despite its ‘‘status’’ of immune-privileged site, both
innate and adaptive inflammatory responses occur and are
involved in several pathological conditions. A number of
studies have evaluated the role of TRAIL and of TRAIL-
related pathways as pro-inflammatory or protective stimuli,
depending on the specific pathological condition, con-
firming a twofold nature of this molecule. In this light, the
aim of this review is to summarize the main preclinical
evidences of the potential/involvement of TRAIL molecule
and TRAIL pathways for the treatment of central nervous
system disorders and the key suggestions coming from
their assessment in preclinical models as proof of concept
for future clinical studies.
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Introduction
The acronym TRAIL designates a member of the tumor
necrosis factor (TNF) family first reported in the 1990s by
two independent studies. Both described TRAIL, TNF-re-
lated apoptosis-inducing ligand, as a protein able to
mediate cell signals triggering caspase activation and
programmed cell death in several cell types [1, 2].
Although interest in its biological features has primarily
been focused on its anti-cancer activity [3–7], growing
attention is also being paid to TRAIL involvement in both
normal immunological homeostasis, and the develop-
ment/monitoring of pathological conditions, by virtue of its
involvement in different processes of the innate and
adaptive immune systems. In this light, our group has
extensively contributed to demonstrate an inverse correla-
tion between the circulating levels of TRAIL and the
chronic inflammation present in several pathological set-
tings, suggesting that TRAIL may have potential as a
biomarker. We have also shown that low levels of TRAIL
are associated with total and cardiovascular mortality in
older adults and interestingly, we have demonstrated that
17-b estradiol could play a role in regulating the amount of
TRAIL in circulation by mediating downregulation of
TRAIL expression [8, 9]. In addition, and in line with other
reports, we have shown that TRAIL is inversely associated
with outcome and mortality in patients with several
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pathological conditions, which include chronic kidney
diseases, heart/kidney transplant, and cardiovascular dis-
orders such as acute myocardial infarction, heart failure,
and coronary heart disease [10–15]. More recently, clinical
studies have shown significant changes in the circulating
levels of TRAIL in patients affected by Type 1 [16, 17] and
Type 2 [18, 19] diabetes mellitus [20], confirming the
results of previous in vitro and in vivo preclinical studies
that suggested a general protective effect of TRAIL in the
development/progression of diabetes and diabetes-related
complications [21–24].
However, the role of TRAIL seems to be fairly
ambiguous, with different reports suggesting conflicting
roles for TRAIL in the development/control of several
pathological conditions. This apparently paradoxical
behavior has recently been highlighted and reviewed on
rheumatoid arthritis [25], for example, in which some
reports implicate TRAIL in its pathogenesis, while others
suggest it may have a protective effect, potentially by
controlling synovial hyperplasia and immune cell hyper-
activation and acting as a prognostic factor [25, 26]. A
possible protective role of TRAIL has also emerged from
preclinical [27] and clinical studies in atherogenesis [28],
which seem to indicate that TRAIL acts to control home-
ostasis in atherosclerotic blood vessels. However, there
may also be a harmful relationship between levels of
TRAIL and vascular inflammation and atherosclerosis, and
this requires further investigation [29]. Similarly, while
some authors report a potential involvement of endogenous
TRAIL in the development of allergic asthma in preclinical
models [30], we, among others, have shown that soluble
exogenous TRAIL appears to play a protective role in the
resolution phase of asthma in a model of chronic allergen
inhalation [31, 32].
It appears therefore that the activities and functions of
TRAIL are extremely complex, being the result of the
involvement of multiple pathways and of multiple levels of
control, with each depending upon the specific cell type
and the specific biological/pathological context. Hence,
discovering the interplay between resident and immune
cells may be the key to understanding the development of
several diseases, and could lead to the identification of new
therapeutic targets. Under normal conditions the central
nervous system (CNS) has a so-called ‘‘immune privilege
status’’ characterized by limited local inflammation.
However, in presence of pathological disorders like Alz-
heimer’s disease, multiple sclerosis and local brain injuries
such as ischemic stroke, which all share common features
[33], immune responses are stimulated via activation of
microglia and infiltration of circulating cells [34, 35]. In
order to shed light on the involvement of TRAIL in this
process, starting from our experience and knowledge of the
role of TRAIL in different pathological settings, we set out
to review the state of the art on the role of TRAIL in the
CNS.
TRAIL and TRAIL-mediated signalling
The TRAIL protein is encoded by a gene mapped on
chromosome 3 at position 3q26. This site spans approxi-
mately 20 kb, includes five exons and four introns, and is
regulated by a combination of factors, including tran-
scription factors, epigenetics factors, and the presence of
single-nucleotide polymorphisms and functionally distinct
isoforms [36, 37]. Like other members of the TNF family,
TRAIL protein can be detected as trans-membrane type
protein and as soluble protein [38]. TRAIL exerts its bio-
logical effects through interactions with a complex ligand–
receptor system of five cognate receptors, which can be
bound with different affinities under normal physiological
conditions [39, 40]. In humans, TRAIL is released by
several cell types, and is capable of binding the trans-
membrane pro-apoptotic death receptors TRAIL-R1/DR4
and TRAIL-R2/DR5. It also binds to the two transmem-
brane decoy receptors TRAIL-R3/DcR1 and TRAIL-R4/
DcR2, which lack an intact death domain. The fifth element
of the TRAIL receptor system is osteoprotegerin (OPG),
originally discovered as a mediator of osteoclastogenesis
regulation via interaction with the receptor activator of
NFjB ligand (RANKL) [41–47]. OPG is a secreted protein
that lacks both transmembrane and cytoplasmic domains; it
is able to bind not only RANKL, but also TRAIL, for
which it acts as a soluble neutralizing receptor [3]. Inter-
estingly, mice, unlike humans, only have one TRAIL
receptor containing a death domain DD (mDR5); this,
however, does show 60 % sequence homology with human
DR4 and DR5 [1]. Mice also have the two decoy receptors,
mDcR1 and mDcR2, that correspond to human decoy
TRAIL receptors DcR1 and DcR2, albeit with differences
in sequence structures. These findings suggest that TRAIL
decoy receptors are a relatively recent evolutionary event
[48].
As previously mentioned, the best characterized bio-
logical function of TRAIL is its ability to induce apoptosis
in various cancer cells types [49–51]. This is mediated by
its two death-domain-containing receptors, whereas
TRAIL-DcR1, TRAIL-DcR2 and OPG are considered
neutralizing or regulatory receptors [52]. Signals resulting
from death-domain–ligand interaction can induce apoptosis
via assembly of the death-inducing signalling complex
(DISC) [53]. This is formed by the Fas-associated death
domain (FADD), which promotes autocatalytic processing
of caspases, activation of caspases, and thereby apoptosis
[53].
Two TRAIL-activated death pathways have been iden-
tified, an extrinsically mediated death pathway, found in
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cells generating enough caspase-8 (or -10) activation and
apoptotic signalling to promote cell death, and a second
death pathway in cells that require additional processes to
lead to full apoptosis through cleavage of the pro-apoptotic
protein BH3 interacting-domain (Bid) (Fig. 1). However,
TRAIL can also activate other signal transduction path-
ways [53]. The binding of TRAIL to its cognate receptors
can promote non-apoptotic, pro-survival and proliferation
signals through several intracellular molecular mediators,
including the transcription factor nuclear factor-jB (NF-
jB), the mitogen-activated protein kinases (MAPKs), and
PI3K/Akt and ERK pathways, and ultimately leading to
transcription of survival genes able to regulate develop-
mental and inflammatory processes (Fig. 1) [54, 55]. For
initiation, such pathways rely on the recruitment of adaptor
molecules such as TNF-receptor-associated death domain
protein (TRADD), TNF-receptor-associated factor-2
(TRAF2), receptor interacting protein (RIP1), and apop-
tosis inhibitor proteins, which assemble into a complex that
mediates intracellular signal transmission (Fig. 1).
The ‘‘cell selectivity’’ of TRAIL in inducing apoptosis is
directed towards transformed/infected cells, leaving non-
tumor cells largely unaffected, and has therefore been the
focus of much scientific interest. However, increasing
experimental evidence suggests that TRAIL might have
several alternative roles in normal cells/tissues. Our group
has already shown that TRAIL promotes the survival/pro-
liferation of endothelial cells, suggesting that the TRAIL/
TRAIL-R system plays an important role in endothelial cell
physiology and the biology of the vascular system [56], and
affects the survival, migration and proliferation of vascular
smooth muscle cells through activation of specific intra-
cellular pathways [57]. TRAIL can also promote pro-
survival/proliferative effects and interfere with differenti-
ation processes in several other cell types, including
multipotent stem cells, osteoclasts, myeloid cells and
intestinal cells [58–63], and can even, paradoxically, acti-
vate pro-survival pathways in sensitive neoplastic cells
[55]. These contrasting biological effects (prolifera-
tion/survival versus apoptosis) seem to depend on the type
of cells involved, and remains one of the most fascinating
features of TRAIL biology.
In this regard, one hypothesis considers the different
cell-related susceptibility to TRAIL as the result of dif-
ferent patterns of TRAIL receptors expression, specifically
a different ratio between pro-apoptotic (DR) and decoy
(DcR) receptors [54, 64]. The concept of ‘‘lipid rafts’’ has
been introduced to describe plasma membrane platforms
involved in mediate death receptor signals [65]. Struc-
turally, these are dynamic pools rich in cholesterol and
sphingolipids. They are able to trigger TRAIL-DISC-ini-
tiated intracellular apoptotic signals, and some reports
suggest that a redistribution of TRAIL receptors and DISC
composition from ‘‘non rafts’’ to ‘‘lipid rafts’’ could explain
the switching between proliferative/survival and apoptotic
TRAIL-mediated cell pathways in different cellular
Fig. 1 Schematic
representation of TRAIL
signalling pathways. The picture
is a schematic representation of
the main molecular mediators
involved in the TRAIL-
mediated apoptosis (both
intrinsic and extrinsic pathways)
and TRAIL-mediated cell
survival, induced by the
interaction between TRAIL and
its receptors. On the upper
panel, a schematic
representation of the five
cognate TRAIL receptors is
shown. DcR1 and DcR2 are
decoy receptors for TRAIL as
well as the soluble
osteoprotegerin
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contexts [65–68]. Unsurprisingly, both the role and distri-
bution of TRAIL receptors and the ratio between DR and
DcR are still under debate and evaluation [69, 70].
The expression of TRAIL/TRAIL receptors in the brain
has been analyzed by two independent groups, finding that
the cytokine is virtually absent in healthy tissue, with only
low levels of TRAIL ligand expression on oligodendro-
cytes [71, 72]. Nevertheless, both groups found similar
DR4 and DR5 expression profiles, but some differences in
patterns of expression of decoy receptors [71, 72]. In par-
ticular, Cannella et al. reported oligodendrocytes and
neurons as the main cells expressing DcR1, and microglia
the main cells expressing DcR2, while Dorr and colleagues
reported that DcR1 and DcR2 were predominantly
expressed by neurons and oligodendrocytes/neurons,
respectively [71, 72]. This different pattern of expression
of the components of the TRAIL-system in the CNS, dif-
ferentially regulated in the presence of a local disease,
suggest the presence of TRAIL-mediated mechanisms in
the CNS. Moreover, evidence that brain tissue is suscep-
tible to TRAIL-induced apoptosis [73] raises the
hypothesis of a potential dual role of TRAIL in the CNS:
on one hand leading to the activation of apoptotic pathways
behind cell damage and disease progression, and on the
other an overall protective/pro-survival effect, supporting
the manipulation of the TRAIL system for therapeutic
purposes [74].
Perspectives of TRAIL in Alzheimer’s disease
Alzheimer’s disease (AD) is an irreversible, progressive
degenerative disorder that leads to gradual cognitive
impairment characterized by memory loss, reduction of
intellectual abilities, changes in personality and behavior,
and onset of dementia [75]. Occurring in hereditary and
sporadic forms, the clinical features of AD are the result of
the gradual malfunctioning and death of neurons, mainly in
the cortex and hippocampus, due to accumulation of
extracellular amyloid plaques and intracellular neurofib-
rillary tangles [75, 76]. Inflammatory processes are also
involved in the pathological progression of the disease, and
may even be the cause or driving force behind it [77]. In
this regard, TRAIL is specifically expressed in the brains of
AD patients, which display a TRAIL-specific immunore-
activity mainly localized in AD-affected regions, such as
the cerebral cortex, often in the proximity of Congo-red-
positive amyloid plaques [78]. Furthermore, preclinical
in vitro cellular models have implicated TRAIL in the beta-
amyloid protein-dependent cell death known to contribute
to the neurodegenerative process and associated chronic
inflammation characteristic of AD [79]. Indeed, specific
blockade of the TRAIL death receptor DR5 has been
shown to completely prevent amyloid beta-related
neurotoxicity in two cellular models, a neuronal cell line
and primary cortical neurons, suggesting a key role for
DR5 in the TRAIL-induced death pathway in AD [80].
Moreover, the vascular deposition of amyloid beta, which
alters cerebral blood flow and thereby contributes to cog-
nitive impairment in AD seems to be mediated by DR4 and
DR5 death receptors, via both caspase-8- and caspase-9-
triggered apoptotic pathways in human cerebral
microvascular endothelial cells [81].
More recently, the role of TRAIL as a mediator of
amyloid-beta neurotoxicity has been explored as a potential
therapeutic target for the treatment of AD in a triple
transgenic mouse model of AD [82]. In their work Can-
tarella and colleagues have demonstrated that blocking
TRAIL release and activation of apoptotic TRAIL recep-
tors by means of a neutralizing monoclonal antibody can
attenuate amyloid-beta-induced neurotoxicity [82]. In par-
ticular, treatment via intraperitoneal infusion started
6 months before the onset of the disease led to reduced
amyloid-beta deposition, functional improvement, and a
reduction in the inflammatory response in the brain,
resulting in a significant overall improvement in cognitive
parameters [82].
Evidence that there is no difference in circulating levels
of TRAIL between AD patients and healthy controls seems
to suggest that this effect is local and restricted to the CNS
[83]. It may be that TRAIL is released by neurons in
response to local stress generated by the accumulation of
oligomers of amyloid-beta. Alternatively, it could be
released by infiltrating immune cells or other cell types
reacting to amyloid-b oligomers or increased neuronal
signals [84]. Although several aspects of this approach
evidently still need to be refined, this can nevertheless be
considered a proof of concept that targeting amyloid
pathology via manipulation of TRAIL pathways may be a
new therapeutic approach for the clinical management of
AD patients.
Perspectives of TRAIL in multiple sclerosis
and secondary cognitive impairment
Multiple sclerosis (MS) is a demyelinating disease of the
central nervous system, and primarily the result of an auto-
inflammatory reaction, although genetic predisposition and
environmental factors may be implicated [85] and it still
represents one of the major causes of chronic neurological
disability. Even though its own etiology remains unclear, it
is known, however, that the major feature of the disease is
the disruption of the myelinated tracts of the CNS by auto-
reactive lymphocytes [86]. This leads to cumulative and
irreversible damage, as well as progressive disability [86].
In its early stages, this pathological cascade appears to be
driven by a peripheral immune response targeting the CNS,
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followed by a later progressive phase characterized by
local immune reactions within the CNS [87]. According to
a recent review of the state of the art in MS, the main
processes leading to neurodegeneration include microglia
activation, chronic oxidative injury, accumulation of
mitochondrial damage in axons, and age-related iron
accumulation in the human brain [88].
Research in the field of MS takes advantage of the
availability of murine models of the disease, including
experimental autoimmune encephalomyelitis (EAE), pro-
viding insights into the biological processes and
development/progression of MS [89]. Although no single
model can replicate the complexity of MS and all its
pathogenic pathways [89], preclinical evidences show that
blockade of the TRAIL-pathway in mice by various
approaches exacerbated EAE, increasing both disease score
and the degree of inflammation in the CNS, while treatment
with recombinant soluble TRAIL delayed disease onset and
reduced the severity of EAE [90, 91]. It appears that
TRAIL-mediated effects were not related to apoptosis
induction in inflammatory cells, but rather to the prevention
of autoreactive T cell activation [90–92]. In addition to its
influence on T cell growth/functionality, there is evidence
that TRAIL is involved in triggering and promoting
CD4?CD25? regulatory T cells [93]. Nevertheless, a
TRAIL-mediated contribution to cell damage in the CNS in
the presence of neuroinflammation has also been reported
[94], confirming that this molecule has a dual role, pro-
voking different outcomes when peripheral or central
tissues are involved and inducing contrasting effects at
different stages in the course of the disease. It is evident that
these two ‘‘sides’’ of TRAIL, anti-inflammatory and pro-
apoptotic, could be targeted differently for the same thera-
peutic purpose in EAE/MS, and, indeed, the therapeutic
potential of targeting the TRAIL system to manage EAE
has recently been explored using different approaches. In
one study, a fusion protein between the extracellular
domain of fibroblast growth-factor-inducible 14, formally
the cell surface receptor for the TNF family member
inducer of apoptosis TWEAK, and the extracellular domain
of TRAIL was designed as an anti-inflammatory agent [95].
Injected daily at different time points after disease induction
in mice, the fusion protein brought about clinical
improvement correlated with: (1) decreasing lymphocyte
infiltrate in the CNS; (2) decreased Th1/Th17 responses,
and (3) increased number of regulatory T cells [95]. Simi-
larly, prior to the onset of EAE, intrathecal delivery of a
plasmid DNA coding for a fusion protein between TRAIL
and OX40, a member of the TNF receptor super family
predominantly expressed on activated T cells, reduced
disease severity and inflammatory cell infiltrates [96].
As higher TRAIL levels have been reported in estab-
lished MS lesions [71, 72], and affected brains show a
different pattern of death receptor expression than healthy
controls, the TRAIL system could play an important role in
the pathological process of MS [71, 72]. In the light of the
body of evidence coming from preclinical EAE model,
attention has turned to TRAIL as a potential clinical bio-
marker in MS, focusing also on the possible link between
gene polymorphisms of TRAIL system components and the
clinical course of the disease. Although a recent study
reported no difference in serum TRAIL levels between MS
patients and healthy controls, comparative analysis of
patients reporting different clinical forms and activity
phases of the disease showed that TRAIL is significantly
reduced during relapse in relapsing-remitting MS patients
[97]. In the same context, other authors have reported
lower serum levels of soluble TRAIL protein in MS
patients with respect to healthy controls but they found no
differences in the expression ratio of the TRAIL mRNA
gene expression ratio [98].
These discrepancies suggest the need for larger cohort of
patients and appropriate functional studies, in particular to
investigate whether the TRAIL levels observed in MS
patients are associated with enhanced survival of patho-
genic T lymphocytes and other inflammatory markers.
Moreover, since TRAIL has been suggested to be involved
in Interferon beta (IFN-b) activity, the assessment of its
expression has been proposed as potential prognostic
marker of treatment response to IFN-b in MS patients [99,
100]. Other lines of evidence suggest that genetic variants
of the TRAIL and TRAIL-receptor genes may be associ-
ated with MS susceptibility as reported by studies
considering different single-nucleotide polymorphisms and
splice variants in different cohorts of patients [101–103].
However, larger sample sizes are required to confirm the
preliminary results indicating that splice variants of the
TRAIL system could have a potential as predictors of IFN-
b treatment in MS patients [104].
The role of TRAIL has also been evaluated in other
cognitive impairment conditions, often secondary mani-
festations of specific primary diseases such as viral
infection, or the result of distress related to depression or
drug use. For instance, despite considerable advances in
treatment, neurocognitive impairment still occurs in HIV-
infected subjects, whether asymptomatic, mild neurocog-
nitive disorder or HIV-associated dementia (HAD) [105].
This may be due to the virus infecting the perivascular
macrophages and microglia in the brain and the release of
viral proteins that directly kill neurons [105], or inflam-
mation and neuron loss may be ascribable to inflammatory
mediators released from the macrophages and microglia
activated in response to HIV infection [105]. In the context
of HAD, TRAIL has been shown to actively participate in
neuron loss [106] by inducing apoptosis in HIV-1-infected
macrophages and cultured neurons [106]. TRAIL levels are
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increased in human monocyte-derived macrophages after
HIV-1 infection and it is known to be mediated by IRF-1,
IRF-7, Type-I IFNs, and STAT-1 [107].
In psychiatric disorders, which are associated with
neuroendocrine changes, a recent study has evaluated the
pattern of expression of circulating cytokines in the search
for potential biomarkers [108]. The results show that 13
cytokines, including TRAIL-R4, are overexpressed in
individuals with major depressive disorder reporting
childhood trauma, suggesting a relationship between
depression and cytokine alterations [108]. Moreover, in
line with the evidence that drug abuse affects the inflam-
matory system, another recent study has analyzed the
plasma levels of soluble receptors/ligands in cocaine-de-
pendent subjects experiencing or not early life stress in
comparison with control subjects [109]. TRAIL levels were
higher in cocaine-dependent subjects experiencing early
life stress, which, although failing to reach statistical sig-
nificance, does indicate a possible link with circulating
levels of pro-inflammatory mediators [109].
Perspectives of TRAIL in ischemic stroke
Ischemic stroke results in a cascade of events involving
neuronal death, alteration of the white matter pathophysi-
ology, and local inflammation. The resulting clinical
picture is so complex that, while trials testing a preventive
approach have gained major successes in recent years, the
search for effective acute stroke treatments has encoun-
tered many failures. This suggests that successful
translation of biological/pathophysiological knowledge
into effective clinical approaches will definitely require an
integrative approach [110]. In particular, the cerebral
inflammation, the biological significance of its resolution,
and the repair of neuronal damage, have been recently
reviewed focusing in particular on the role of the so-called
DAMPs, i.e., molecules released from damaged cells that
play a key role in triggering local inflammation [111].
During ischemic stroke, activation of the microglia is fol-
lowed by local recruitment of leukocytes to the brain
lesion, thereby contributing to the tissue injury pathogen-
esis [112–114]. In this context, TRAIL seems to play a role
in inducing apoptosis, as evidenced in preclinical models
[115, 116] that highlight the involvement of TRAIL in
neuronal apoptosis in vivo after ischemia. This apparently
occurs through a c-Jun-mediated signalling pathway that
was completely prevented by immunosuppressant treat-
ment [115].
In a murine model of global cerebral ischemia, expres-
sion and upregulation of both TRAIL and its receptor DR5
have been shown after transient ischemia–reperfusion
[117]. Expression of TRAIL was more selective to astro-
cytes and activated microglia/macrophages, while the DR5
receptor was more predominantly expressed in neurons
[117]. In the same model, functionally inhibiting TRAIL
by blocking its interaction with DR5 led to reduced
apoptosis and a neuroprotective effect overall [117]. Other
recent studies have confirmed the overexpression of
TRAIL and TRAIL receptors in hypoxic brain [118, 119],
and the local expression of decoy receptors for TRAIL has
been shown to confer neuronal protection against lethal
ischemia after ischemic preconditioning [120]. In particu-
lar, Cantarella and colleagues have shown that TRAIL is
upregulated in focal ischemia, while it appears to be
downregulated in sub-lethal brain ischemia and brains
subjected to preconditioning stimulus [119]. In this model,
neuroprotection elicited by ischemic preconditioning was
found to occur through both upregulation of TRAIL decoy
receptors and downregulation of its death receptors, as well
as TRAIL itself, which indicated that TRAIL inhibition
may significantly limit tissue damage and promote func-
tional recovery [119].
Recent clinical trials have assessed TRAIL as a potential
biomarker for acute stroke and stroke subtypes. However, a
study performed in plasma samples of patients with recent
lacunar infarcts (silent brain infarcts) revealed no signifi-
cant difference in TRAIL levels with respect to healthy
controls [121]. Nonetheless, in a recently published study
performed in a cohort of patients with acute ischemic
stroke, significant negative correlations between serum
TRAIL levels and both clinical score and stroke volume
have been reported, with no difference between the various
stroke subtypes analysed, in line with findings reported in
other cardiovascular diseases [122].
Concluding remarks
In line with findings obtained in other inflammatory con-
ditions, the overall message from the recently published
results is that TRAIL also plays a dual role in inflammatory
disorders of the CNS, likely as the result of different
involvement/effects of TRAIL pathway in local and
peripheral inflammatory processes. In terms of future
clinical perspectives, therefore, TRAIL appears to be an
attractive therapeutic target, and TRAIL-based approaches
interfering with TRAIL pathways have already demon-
strated therapeutic potential, particularly in Alzheimer’s
disease and EAE/MS (Fig. 2). Moreover, preliminary evi-
dence seems to suggest a potential role of circulating
TRAIL as a biomarker for CNS-related disorders such as
neurocognitive impairment and depression. Nevertheless,
further investigation is required in order to: (1) clarify the
local molecular insights into the mechanisms of action of
TRAIL; (2) evaluate possible TRAIL-based treatment
strategies, taking opportunely into account the different and
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complex immunological features of the specific neurolog-
ical disorders; and (3) develop appropriate delivery
systems for both systemic and local approaches based on
the specific molecular/clinical features of the diseases in
question.
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